Chemists Created Powerful New Tools to Control 2-AG Production and Breakdown
Scientists synthesized compounds that inhibited the 2-AG-producing enzyme DAGLalpha at nanomolar concentrations with high selectivity, creating precision tools for studying endocannabinoid signaling.
Quick Facts
What This Study Found
Researchers synthesized 21 analogues of tetrahydrolipstatin (THL, the active ingredient in the weight-loss drug orlistat) and tested them as inhibitors of 2-AG metabolism.
Three compounds (11, 13, and 15) inhibited DAGLalpha (the enzyme that produces 2-AG) with IC50 values below 50 nanomolar, making them 20 times more potent than the parent compound THL. Critically, they were 23- to 375-fold selective for DAGLalpha over MAGL (which breaks down 2-AG), CB1/CB2 receptors, and FAAH.
One compound (8) was a potent inhibitor of MAGL-like activity (IC50 = 0.41 micromolar) with approximately 7-fold selectivity over other targets.
These selective tools allowed researchers to separately manipulate 2-AG production and degradation, enabling more precise studies of endocannabinoid function.
Key Numbers
Compounds 11, 13, 15: DAGLalpha IC50 < 50 nM (vs. THL IC50 = 1 micromolar). Selectivity: 23-375 fold vs. MAGL, CB1/CB2, FAAH. Compound 8: MAGL IC50 = 0.41 micromolar, 7-fold selective.
How They Did This
Medicinal chemistry study synthesizing 21 THL analogues. Compounds were tested against DAGLalpha, MAGL, CB1, CB2, and FAAH in standardized biochemical assays to determine potency and selectivity.
Why This Research Matters
Selective pharmacological tools are essential for understanding which aspects of endocannabinoid signaling produce specific biological effects. These compounds allowed researchers to ask whether reducing 2-AG production versus enhancing it by blocking breakdown produces different outcomes.
The Bigger Picture
These research tools contributed to the understanding that the endocannabinoid system can be modulated at multiple points (synthesis, degradation, receptor) with different therapeutic profiles. This precision approach has guided the development of endocannabinoid-targeting medications.
What This Study Doesn't Tell Us
These are tool compounds, not drug candidates. In vitro potency and selectivity may not translate to in vivo utility. No behavioral or physiological testing was reported. Long-term safety profiles were not assessed.
Questions This Raises
- ?What happens when 2-AG synthesis is selectively blocked in vivo?
- ?Could DAGLalpha inhibitors have therapeutic applications in conditions with endocannabinoid excess?
Trust & Context
- Key Stat:
- New DAGLalpha inhibitors 20x more potent than parent compound with 23-375 fold selectivity
- Evidence Grade:
- This is a medicinal chemistry study producing research tools. It provides robust in vitro data but no biological or clinical evidence.
- Study Age:
- Published in 2008. DAGLalpha and MAGL inhibitors have since become standard research tools, and some MAGL inhibitors have entered clinical trials.
- Original Title:
- Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism.
- Published In:
- Journal of medicinal chemistry, 51(21), 6970-9 (2008)
- Authors:
- Ortar, Giorgio, Bisogno, Tiziana(3), Ligresti, Alessia(2), Morera, Enrico, Nalli, Marianna, Di Marzo, Vincenzo
- Database ID:
- RTHC-00324
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is DAGLalpha?
Diacylglycerol lipase alpha (DAGLalpha) is the enzyme that produces 2-AG, one of the brain's two main endocannabinoids. Blocking this enzyme reduces 2-AG levels, while blocking MAGL (which breaks down 2-AG) increases them.
Why does selectivity matter?
A selective compound affects only its intended target, not related proteins. High selectivity means researchers can be confident that observed effects come from the specific enzyme they inhibited, not from accidental effects on cannabinoid receptors or other enzymes.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-00324APA
Ortar, Giorgio; Bisogno, Tiziana; Ligresti, Alessia; Morera, Enrico; Nalli, Marianna; Di Marzo, Vincenzo. (2008). Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism.. Journal of medicinal chemistry, 51(21), 6970-9. https://doi.org/10.1021/jm800978m
MLA
Ortar, Giorgio, et al. "Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism.." Journal of medicinal chemistry, 2008. https://doi.org/10.1021/jm800978m
RethinkTHC
RethinkTHC Research Database. "Tetrahydrolipstatin analogues as modulators of endocannabino..." RTHC-00324. Retrieved from https://rethinkthc.com/research/ortar-2008-tetrahydrolipstatin-analogues-as-modulators
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.